Celgene Corp

In Q3 2019, Citadel Advisors’ portfolio of publicly traded securities was worth $212.04 billion. In Q2 2019, its portfolio was worth $155.1 billion.

In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

On November 14, The George Soros Fund Management LLC filed 13F. The firm’s total market value was around $3.6 billion at the end of Q3 2019.

At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.

Tudor Investment founder Paul Tudor Jones II’s macro investment strategies have helped investors understand the opportunities in various securities.

Renaissance Technologies had a strong investment in the healthcare sector in Q2 2019. The healthcare sector makes up 18.16% of the firm’s total portfolio.

On August 26, Amgen (AMGN) announced the purchase of leading immunology drug Otezla from Celgene (CELG) for a cash consideration of $13.4 billion.

Revenue for Bristol-Myers Squibb’s (BMY) Opdivo has grown by a double-digit percentage YoY (year-over-year) since 2016.

In fiscal 2019, Pfizer (PFE) expects its adjusted diluted EPS to fall 4.0% YoY (year-over-year) to $2.83–$2.93.

The consensus recommendation for Bristol-Myers Squibb is a “buy,” while the consensus for Celgene is a “hold.”

Starboard Value has decided to give up the proxy war to stop Bristol-Myers Squibb’s deal with Celgene.

On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).

AbbVie (ABBV) and Celgene (CELG) reported dividends per share of $3.59 and $0.0, respectively, in 2018.

On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an adjusted gross margin of 82.5% in 2019.

On January 3, Bristol-Myers Squibb (BMY) issued a press release announcing that it had entered into a definitive agreement to acquire Celgene.

On February 5, AbbVie (ABBV) closed at $79.69, 1.48% higher than its previous closing price, 5.17% higher than its 52-week low of $75.77.

On January 7, 2019, Celgene (CELG) issued a press release announcing its strategy to maximize the commercial potential of its major revenue-earning hemato-oncology assets.

On January 7, Celgene (CELG) issued a press release announcing that the company earned revenues of $15.2 billion for fiscal 2018.

Ray Dalio thinks of the markets in the context of the economic machine, wherein cycles repeat themselves.

Bristol-Myers Squibb’s (BMY) acquisition of Celgene (CELG) will add the latter’s blockbuster multiple myeloma (or MM) drugs, Revlimid and Pomalyst, to the company’s portfolio.

Bristol-Myers Squibb (BMY) will target four major therapeutic areas after completing the acquisition of Celgene (CELG).

According to Bristol-Myers Squibb’s (BMY) investor presentation, the company expects to create a leading oncology franchise across both solid tumor and hematologic malignancy segments.

According to Bristol-Myers Squibb’s (BMY) press release, the company expects the acquisition of Celgene (CELG) to result in annual cost synergies close to $2.5 billion.

Bristol-Myers Squibb (BMY) expects to report GAAP EPS in the range of $3.05 to $3.15 and non-GAAP EPS in the range of $3.80 to $3.90 for fiscal 2018.

In its third-quarter earnings conference call, Bristol-Myers Squibb (BMY) has forecasted high-single-digit YoY revenue growth for fiscal 2018.

The acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) brings together both the company’s leading franchises.

Bristol-Myers Squibb has agreed to acquire Celgene in a cash and stock transaction valued at around $74.0 billion.

Today, Bristol-Myers Squibb (BMY) is trading at $45.85, ~11.86% lower than its previous day’s closing price.

In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

In its third-quarter earnings conference call, Celgene (CELG) reiterated its expectation for Abraxane’s fiscal 2018 net product sales of around $1.0 billion.

In its third-quarter earnings conference call, Celgene (CELG) reiterated its expectation for Pomalyst fiscal 2018 net product sales of around $2.0 billion.

On October 23, 2018, Celgene issued a press release announcing favorable results from open-label Phase 2/3 trial, ECOG E3A06, evaluating Revlimid in the smoldering multiple myeloma (or MM) indication.

In its third-quarter earnings conference call, Celgene (CELG) reiterated its expectation for Revlimid’s fiscal 2018 net product sales of around $9.7 billion.

Celgene (CELG) is focused on advancing its diversified inflammation and immunology (or I&I) research pipeline in 2018.

In the first nine months of 2018, Celgene’s (CELG) Otezla reported worldwide sales of $1.16 billion.

In its third-quarter earnings conference call, Celgene (CELG) has revised its fiscal 2018 net product sales guidance for Otezla from the previously projected $1.5 billion to $1.6 billion.

In its third-quarter earnings conference call, Celgene (CELG) revised its GAAP operating margin guidance for fiscal 2018 from 35% to 34%.

Wall Street analysts expect Celgene to report revenues of $15.22 billion in fiscal 2018.

Celgene reported Q3 revenues of $3.89 billion, a YoY rise of 18.2%. The company managed to surpass consensus revenue estimates by $40 million.

On November 19, AstraZeneca’s (AZN) stock price closed at $40.80, which represents ~5% growth from its closing price of $38.78 on October 31.

On October 25, Merck (MRK) announced a dividend of $0.55 per share for its outstanding common stock in the fourth quarter of 2018.

Celgene’s (CELG) Otezla reported revenues of $432.0 million in the third quarter, a ~40.3% YoY increase.

Analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018.

Johnson & Johnson’s (JNJ) oncology business generated revenue of $2.6 billion in the third quarter.

For Biogen, eight analysts recommended a “strong buy,” 12 recommended a “buy,” and nine recommended a “hold.”

Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.

In the multiple myeloma market, Celgene leads the immunomodulatory agent class of drugs with Revlimid, Pomalyst, and Thalomid.

Celgene is expected to report its third-quarter earnings on October 25. Celgene is expected to generate revenues of $3.8 billion in the third quarter.

Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017.

Wall Street analysts expect Allergan to report EPS of $3.98 on revenues of $3.8 billion in the third quarter.

Ionis’s Commercial Revenues segment reported second-quarter revenues of $57.0 million, compared to $24.0 million during the second quarter of 2017.

On September 20, Allergan (AGN) announced a partnership with actor Scott Eastwood to encourage the recognition of World Alzheimer’s Day on September 21.

Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders.

Celgene has completed patient enrolment in TRANSCEND, a Phase 1/2 trial evaluating JCAR017 for treating diffuse large B-cell lymphoma.

Roche’s (RHHBY) Pharmaceuticals division reported revenues of 21.8 billion Swiss francs in H1 2018 compared to 20.5 billion Swiss francs in H1 2017, reflecting ~7% YoY growth.

On its second-quarter earnings conference call, AbbVie (ABBV) raised its 2018 EPS guidance by $0.10.

On July 25, Biogen (BIIB) and Eisai announced positive results from the Phase 2 study evaluating BAN2401 in early Alzheimer’s disease.

Allergan (AGN) is developing a variety of products through internal programs as well as in collaboration with other companies.

As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter.

Bausch Health Companies reported revenue of $2.1 billion in the second quarter, reflecting a ~5% YoY (year-over-year) fall and a ~3% YoY organic rise.

In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.

Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.

Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.

In the second quarter of 2018, Merck (MRK) generated revenues of $10.5 billion, which reflected 5% growth on a year-over-year (or YoY) basis and 4% growth sequentially.

Zyprexa reported revenues of $128.0 million in Q2 2018, a 9.0% decline in YoY revenues compared to $140.8 million in Q2 2017.

Shire (SHPG) beat Wall Street analysts’ estimates for revenues and EPS. It reported non-GAAP EPS of $3.88 on revenues of $3.9 billion in Q2 2018.

Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018.

As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter.

Alnylam Pharmaceuticals’ (ALNY) selling, general, and administrative expenses are expected to rise 73.46%.

Merck (MRK) generated revenues of $10.5 billion in the second quarter, reflecting ~5.0% year-over-year growth.

Amgen (AMGN) reported in Q2 2018 results yesterday, surpassing analysts’ EPS and revenue estimates.

In the second quarter of 2018, Celgene (CELG) reported revenues of $3.8 billion, compared to $3.3 billion in the second quarter of 2017.

Vertex Pharmaceuticals (VRTX) is expected to incur selling, general, and administrative expenses of $117.10 million in Q2 2018 as compared with $92.91 million in Q2 2017.

Gilead Sciences’ (GILD) research and development expenses are expected to increase 8.78%, from $812 million in Q2 2017 to $883.27 million in Q2 2018.

AstraZeneca (AZN) is expected to incur research and development expenses of $1.26 billion in Q2 2018 as compared with $1.28 billion in Q2 2017.

Celgene’s (CELG) Revlimid and Pomalyst generated revenues of $2.2 billion and $453 million, respectively in the first quarter.

Analysts expect Alexion Pharmaceuticals’ (ALXN) interest expense to decline by 5.32% from $24 million in Q2 2017 to $22.72 million in Q2 2018.

Johnson & Johnson’s (JNJ) Darzalex generated revenues of $432.0 million in Q1 2018 compared to $255.0 million in Q1 2017, reflecting ~69.4% YoY growth.

Today, Celgene (CELG) and Acceleron Therapeutics (XLRN) stocks are trending higher on the news of their Phase 3 clinical trial for luspatercept meeting its goal.

On June 27, Amgen (AMGN) announced the top-line results for the NCT02937701 study—a Phase 3 study evaluating safety and efficacy of ABP 710.

In June 2018, Celgene (CELG) and Bluebird Bio (BLUE) presented updated results from the ongoing phase 1 CRB-401 trial of bb2121.

On June 11, Editas Medicine (EDIT) stock fell 7.8% over concerns that CRISPR CAS-9 Gene Therapy causes cancer.

Following TrovaGene’s pricing announcement, the stock price decreased ~48% to the closing price of $0.92 on June 8.

Sesen Bio (SESN), formerly known as Eleven Biotherapeutics, is developing next-generation antibody-drug conjugate therapies. The stock jumped ~26.1% to $2.27 yesterday.

The FDA approved Amgen’s Blincyto to treat MRD greater than or equal to 0.01% in B-cell precursor ALL patients.

In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.

Scynexis (SCYX) witnessed a 28% rise in its stock price in the week ended May 18.

Amgen (AMGN) stock has risen ~2.3% in the last week following recent drug approvals.

BlueBird Bio stock has risen ~119.9% over the last 12 months and 6.3% year-to-date.

Of the 19 analysts covering Alexion Pharmaceuticals in May, 18 have given the stock “buy” or higher ratings.

Total worldwide sales of Celgene’s other products—including Idhifa, Thalomid, and Istodax—increased from $226.0 million in 1Q17 to $229.0 million in 1Q18.

Celgene entered into a collaboration with BeiGene Limited for advancing the BGB-A317 program, which is targeted at solid tumor cancers.

Of the 30 analysts covering Celgene in May, 15 analysts rated the stock a “buy” or higher, and 14 analysts gave Celgene a “hold” rating.

Celgene’s total worldwide sales of the hematology/oncology category increased from $2.7 billion in 1Q17 to $3.1 billion in 1Q18.

In 1Q18, Celgene’s (CELG) Otezla generated revenue of $353 million compared to $242 million in 1Q17.

In 1Q18, Celgene’s (CELG) revenue grew 20% year-over-year to $3.5 billion from $3.0 billion, boosted by Revlimid, Pomalyst, and Otezla sales.

In 1Q18, Amgen’s (AMGN) Kyprolis revenue grew 17% YoY (year-over-year) to $222 million from $190 million, primarily due to higher unit demand in international markets.

Last big week of earnings kicks off with not a lot to show for it in the market The week of April 30 is an exciting one in terms of earnings, and here are 18 companies we will be watching closely: Monday McDonald’s Corporation (NYSE: MCD) – before the market opens – great year last […]

In 2017, Pfizer (PFE) earned $2.5 billion from sales of Eliquis through direct sales and through its alliance with Bristol-Myers Squibb.

Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.